Medicare may cover Tremfya. However, the medication can be high cost, so a person should check with Medicare or their plan provider beforehand.

From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently ...

Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn's disease, according to Sphe ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Johnson & Johnson's stock still has room to rise after the recent financial results exceeded expectations. Learn how J&J is ...

The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK ...

TREMFYA shows promise in ulcerative colitis treatmentIn the GALAXI 2 & 3 studies for CD, 44% of biologic-naïve patients treated with TREMFYA® every eight weeks and 46.1% of patients with a more ...

Tremfya's growth could come from (1) growth in the psoriasis market or (2) from another product's market share. It could also impact share and pricing of other products.

Do not take TREMFYA® if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA ®. Before using TREMFYA®, tell your healthcare provider about all of your ...

Tremfya and Cosentyx for Psoriasis Treatment Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis ...

BARCELONA - Johnson & Johnson’s (NYSE:JNJ) Tremfya demonstrated significant ability to inhibit joint structural damage progression in patients with active psoriatic arthritis compared to placebo, ...